Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response

摘要: Aliment Pharmacol Ther 31, 1018–1027 Summary Background  Chronic infection with hepatitis C, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of would be as effective, but less toxic standard doses. Aim  To test the hypothesis effective as, than, doses. Methods  A total 30 patients were treated low-dose alfa-2a (90 μg/week) 27 doses (180 μg/week) for 24 weeks in combination 800 mg/day ribavirin. Patients who failed treatment offered 48 weeks standard-dose Viral serum inducible protein 10 (IP-10) levels measured early viral kinetic parameters calculated. Results  Sustained virological response was achieved 68% 87% (per protocol, P = 0.79 non-inferiority). Re-treatment successful all tolerated full duration. The group had greater first-phase declines faster time negativity. second-phase slope not dose-dependent. IP-10 induction significantly dose. Although fatigue general feeling during worse dose, haematological toxicity depression did differ between groups. Conclusion  is associated some symptomatic benefit, equivalent dosing.